World's Best Scientists 2026 revealed!
Award Badge
Best Female Scientists
2025

D-Index & Metrics

Best Female Scientists

D-Index
110
Citations
42633
World Ranking
895
National Ranking
545

Medicine

D-Index
111
Citations
43579
World Ranking
5349
National Ranking
2888

Deborah A. Thomas publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Deborah A. Thomas sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 554 publications — 66th percentile

66% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Deborah A. Thomas D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Deborah A. Thomas sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 111 D-Index — 74th percentile

74% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2025 - Research.com Best Female Scientists Award

Overview

Deborah A. Thomas is a researcher affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their work spans multiple disciplines primarily within Medicine and Social Sciences, with a notable focus on areas such as Genetics, Sociology and Political Science, Epidemiology, Surgery, and Public Health, Environmental and Occupational Health.

Their research topics encompass a range of subjects including Inflammatory Bowel Disease, Microscopic Colitis, Caribbean history, culture, and politics, Cuban History and Society, Helicobacter pylori-related gastroenterology studies, Menstrual Health and Disorders, and Health and Wellbeing Research.

Key recent publications by Deborah A. Thomas include:

  • Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Disease, 2022, Crohn's & Colitis 360
  • A Multimodal Qualitative Approach to Understanding Menstrual Health Equity among Adolescents and Young Adults, 2023, Journal of Pediatric and Adolescent Gynecology
  • 19th Century United States Newspaper images predicted as Photographs with labels for "human", "animal", "human-structure" and "landscape", 2022, arXiv (Cornell University)
  • Displacements, 2020, Small Axe A Caribbean Journal of Criticism
  • Early Treatment with Ofatumumab in Patients with High-Risk CLL, 2022, Blood

Frequent coauthors collaborating with Deborah A. Thomas include:

  • April J. Mayes
  • Patricia Mohammed
  • Martin Munro
  • Michelle Stephens
  • Yolanda Martínez-San

Their work is often published in venues such as:

  • Crohn's & Colitis 360
  • Journal of Pediatric and Adolescent Gynecology
  • Small Axe A Caribbean Journal of Criticism
  • PEDIATRICS
  • Blood

Best Publications

  • Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

    Alan List;Gordon Dewald;John Bennett;Aristotle Giagounidis

  • Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

    Srdan Verstovsek;Hagop Kantarjian;Ruben A. Mesa;Animesh D. Pardanani

  • Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia

    Michael J. Keating;Susan O'Brien;Maher Albitar;Susan Lerner

  • Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.

    Jean Pierre J. Issa;Guillermo Garcia-Manero;Francis J. Giles;Rajan Mannari

  • Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes

    Alvaro Aguayo;Hagop M Kantarjian;Taghi Manshouri;Cristi Gidel

  • Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.

    Constantine S. Tam;Susan O'Brien;William Wierda;Hagop Kantarjian

  • Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia

    Hagop Kantarjian;Deborah Thomas;Susan O'Brien;Jorge Cortes

  • Rituximab Dose-Escalation Trial in Chronic Lymphocytic Leukemia

    Susan M. O’Brien;Hagop Kantarjian;Deborah A. Thomas;Francis J. Giles

  • Treatment of Philadelphia chromosome–positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate

    Deborah A. Thomas;Stefan Faderl;Jorge Cortes;Susan O'Brien

  • Chemoimmunotherapy With Fludarabine, Cyclophosphamide, and Rituximab for Relapsed and Refractory Chronic Lymphocytic Leukemia

    William Wierda;Susan O'Brien;Sijin Wen;Stefan Faderl

  • Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia

    Deborah A. Thomas;Stefan Faderl;Susan O'Brien;Carlos Bueso-Ramos

  • Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q

    Azra Raza;James A. Reeves;Eric J. Feldman;Gordon W. Dewald

  • High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome–positive chronic phase chronic myeloid leukemia

    Hagop Kantarjian;Moshe Talpaz;Susan O'Brien;Guillermo Garcia-Manero

  • Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome–Negative Precursor B-Lineage Acute Lymphoblastic Leukemia

    Deborah A. Thomas;Susan O'Brien;Stefan Faderl;Guillermo Garcia-Manero

  • Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia

    Farhad Ravandi;Jorge E Cortes;Daniel Jones;Stefan H Faderl

  • Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

    Hagop M. Kantarjian;Deborah A. Thomas;Jeffrey L. Jorgensen;Elias Joseph Jabbour

  • Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia.

    William G. Wierda;Susan O'Brien;Xuemei Wang;Stefan Faderl

  • Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia.

    Hagop M. Kantarjian;Moshe Talpaz;Susan O'Brien;Francis Giles

  • Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies

    Karen W.L. Yee;Zhihong Zeng;Marina Konopleva;Srdan Verstovsek

  • Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT).

    Ruben A. Mesa;Srdan Verstovsek;Francisco Cervantes;Giovanni Barosi

Frequent Co-Authors

Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Jorge E. Cortes
Jorge E. Cortes Augusta University
Susan O'Brien
Susan O'Brien University of California, Irvine
Farhad Ravandi
Farhad Ravandi The University of Texas MD Anderson Cancer Center
Guillermo Garcia-Manero
Guillermo Garcia-Manero The University of Texas MD Anderson Cancer Center
Stefan Faderl
Stefan Faderl The University of Texas MD Anderson Cancer Center
Elias Jabbour
Elias Jabbour The University of Texas MD Anderson Cancer Center
Srdan Verstovsek
Srdan Verstovsek The University of Texas MD Anderson Cancer Center
Francis J. Giles
Francis J. Giles Northwestern University
Gautam Borthakur
Gautam Borthakur The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Medicine in the USA opens the door to many rewarding and flexible career paths, especially in the nursing and healthcare professions. Online degree options are making these pathways even more accessible for students balancing work, family, and study.

For current registered nurses aiming to advance their education, rn to bsn online programs offer a flexible route to a bachelor’s degree. Similarly, those interested in educational or leadership positions can consider doctorate in nursing education online programs to further their expertise and open doors to high-level roles.

Prospective students without a nursing background can pursue a nursing career through direct entry msn programs, which provide a streamlined pathway to becoming a registered nurse. Additionally, online bsn programs for non nurses can offer accessible and less competitive entry points into the profession.

Exploring these online options allows students to find degree programs that fit their unique needs and career goals while maintaining the flexibility modern life requires.

Best Scientists Citing Deborah A. Thomas

Trending Scientists